

Tyra Biosciences stock fell sharply as initial dabogratinib Phase 2 data showed a 57% complete response rate at 60 mg.
You can purchase shares of Tyra Biosciences (NASDAQ:TYRA) through any online brokerage.
Other companies in Tyra Biosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Tyra Biosciences has a consensus price target of $43.73.
The stock price for Tyra Biosciences (NASDAQ: TYRA) is $21.65 last updated November 10, 2026 at 9:16 AM EST.
There are no upcoming dividends for Tyra Biosciences.
Tyra Biosciences does not have any upcoming earnings scheduled.
There is no upcoming split for Tyra Biosciences.
Tyra Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor...